Pharmaceuticals Financial News

Subscribe to enjoy similar stories. For Pfizer Inc., the strategy has been “go big, or go home". When the covid-19 pandemic first hit, Pfizer’s big bet on its partnership with BioNTech SE hit a home run.

Eli Lilly & Co has unveiled plans to expand its US manufacturing operations with a $27-billion investment in four new plants set to open in 2025. This brings Lilly’s total US investment to over $50 billion since 2020.

Go Digit General Insurance has acquired a small stake in pharmaceuticals major Dr Reddy’s Laboratories through a cash infusion of Rs 30.06 crore, the insurance company said in a stock exchange filing today.

India's hospital sector is abuzz with feverish deal-making activity. The latest of big deals which are consolidating the sector and bringing big players into it is by a New York-based global private-equity and investment company, KKR, which has bought a controlling stake in leading cancer care hospital chain Healthcare Global (HCG) from private equity peer CVC Capital Partners for nearly $400 million.

Natco Pharma Ltd.(up 2.52 per cent), Glenmark Pharmaceuticals Ltd.(up 1.95 per cent), Laurus Labs Ltd.(up 1.73 per cent), Granules India Ltd.(up 1.56 per cent) and Dr. Reddy's Laboratories Ltd.(up 1.22 per cent) were among the top gainers.

Pfizer zoomed 8.6% to a high of Rs 4,448.35 on the BSE today after the company on Friday announced that it has entered into a marketing and supply agreement with Mylan Pharmaceuticals. This agreement is regarding the sales and marketing of two brands of the company (Pfizer), Ativan and Pacitane.

Gold prices steadied near an all-time high on Monday, supported by concerns over U.S. President Donald Trump's tariff plans, while focus shifted to a key U.S. inflation report due later this week.

Subscribe to enjoy similar stories. New Delhi: The Centre will shortly tap various ministries for inputs on tariff and policy tweaks to enhance market access for American goods and services ahead of upcoming trade talks with the US, four people aware of the plans said. The changes will aim to support US companies, educational institutions, and research in sectors such as space, agriculture, pharmaceuticals and high-value manufacturing.

tapentadol and carisoprodol drugs is not approved in India, and prohibited production and export of such medicines, amid reports that an Indian company has been exporting the unlicensed combination.

KKR has acquired a controlling stake in leading cancer care hospital chain Healthcare Global from private equity peer CVC Capital Partners for Rs 3466 crore ($400 million), doubling down on the healthcare sector that has already seen massive PE-led consolidation.

Jagsonpal Pharmaceuticals for significant manufacturing lapses at its Rajasthan-based active pharmaceutical ingredients (APIs) plant. In a warning letter issued to the company's Managing Director Manish Gupta, the US Food and Drug Administration (USFDA) noted that the correspondence summarizes significant deviations from Current Good Manufacturing Practice for APIs.

options market that could trigger heightened volatility, reported Reuters.

Subscribe to enjoy similar stories. India and the United States agreed to negotiate the first tranche of a mutually beneficial multi-sector bilateral trade agreement (BTA) by late September after president Donald Trump threatened to impose reciprocal tariffs on goods from India and several other countries. As he did in his first term, Trump continues to pressure India to lower its high and protectionist import duties on several goods, including luxury goods.

Gland Pharma Ltd.(up 1.61 per cent), Cipla Ltd.(up 1.1 per cent), Lupin Ltd.(up 0.49 per cent), Zydus Lifesciences Ltd.(up 0.26 per cent) and Glenmark Pharmaceuticals Ltd.(up 0.1 per cent) were among the top gainers.

Subscribe to enjoy similar stories. The scimitar of import tariffs wielded by US President Donald Trump has sent investors and markets scurrying for cover across the world and across industries. On Wednesday, it was the turn of the pharmaceutical industry.

Subscribe to enjoy similar stories. To fix accountability, the government is working on a plan to include the name of the person responsible for releasing a batch of medicines under the Drugs Rules, 1945, according to an official familiar with the matter. This comes against the backdrop of growing complaints about counterfeit and substandard drugs circulating in the market.

Subscribe to enjoy similar stories. In July 2024, Eli Lilly and Co., the pharmaceutical company, announced that it has secured the first approvals for the import and sale of its diabetes and obesity medication, Tirzepatide—sold under the name Mounjaro—in India in 2025.

Goldman Sachs.

Pharmaceutical stocks plunged on Wednesday, with the Nifty Pharma Index dropping over 2%. Leading the selloff, Aurobindo Pharma slumped as much as 9.5% to Rs 1,053.45, making it the biggest loser in the pharma pack, after U.S. President Donald Trump signalled plans to impose a 25% tariff on imported drugs, triggering concerns over higher costs and potential disruptions for Indian drugmakers, which are among the largest suppliers to the U.S. market. Dr. Reddy’s Laboratories slid 5.8% to Rs 1,128.90, while Zydus Lifesciences fell 4.8%. Sun Pharma, India’s largest drugmaker, dropped 3.2% to Rs 1,647.35, emerging as the top loser on the BSE Sensex and among the top five decliners on the Nifty 50 benchmark. Other major pharmaceutical firms also took a hit, with Lupin down 4%, Glenmark Pharma sliding 2.7%, and Cipla losing 2.2%.